Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious disease efforts.

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the ...

May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Presented by Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Moderna’s mRNA flu shot to get FDA review After some initial ...

May 21 (Reuters) - The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot. Moderna's mRNA-based seasonal flu vaccine is currently ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its ...